Want to see FR:ALERS full AI Analyst Report?
ALERS Stock Chart & Stats
€19.80
-€0.30(-1.43%)
At close: 4:00 PM EDT
€19.80
-€0.30(-1.43%)
Day’s Range― - ―
52-Week Range€19.20 - €25.70
Previous CloseN/A
Volume62.00
Average Volume (3M)5.17K
Market Cap
€251.14M
Enterprise Value€203.86
Total Cash (Recent Filing)€20.66M
Total Debt (Recent Filing)€16.02M
Price to Earnings (P/E)35.9
Beta0.19
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,248,871
10 Day Avg. Volume13,979
30 Day Avg. Volume5,170
Financial Highlights & Ratios
PEG Ratio2.53
Price to Book (P/B)1.36
Price to Sales (P/S)1.48
P/FCF Ratio39.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative LeverageDebt-to-equity of about 0.09 and a sizable equity buffer indicate conservative financing. This reduces balance-sheet strain and preserves flexibility to fund product development, distribution expansion, or working-capital needs through the next several quarters.
Positive Cash GenerationPositive operating and free cash flow in every period shown demonstrates that the business converts operations into internally generated funds. That supports ongoing investment and resilience, although recent deterioration means this strength should not be treated as unqualified.
Recurring Consumables ModelSales of continuously consumed IVD tests, reagents, and laboratory consumables can create repeat purchasing, while distribution and service offerings broaden the revenue base. This supports durable customer relationships and more resilient demand across clinical and research markets.
Bears Say
Lower Margin DurabilityNet margin of about 2.9% in 2025, versus exceptionally high levels in 2021–2022, shows earnings power has reset lower. Even with gross margin around 40–46%, thinner operating profitability leaves less room to absorb execution pressure or reinvest.
Weaker Free Cash FlowFree cash flow fell about 16% year over year in 2025 and was far below 2021–2022 levels. This weakening reduces internally funded investment capacity and makes shareholder cash generation less dependable, despite remaining positive overall.
Volatile Capital ReturnsHistorical returns on equity have swung materially, and 2025 ROE is shown as zero. Such inconsistency makes it harder to judge the durability of capital productivity and indicates that reported earnings have not translated into stable returns for shareholders.
Eurobio-Scientific SA News
ALERS FAQ
What was Eurobio-Scientific SA’s price range in the past 12 months?
Eurobio-Scientific SA lowest stock price was €19.20 and its highest was €25.70 in the past 12 months.
What is Eurobio-Scientific SA’s market cap?
Eurobio-Scientific SA’s market cap is €251.14M.
When is Eurobio-Scientific SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Eurobio-Scientific SA’s earnings last quarter?
Currently, no data Available
Is Eurobio-Scientific SA overvalued?
According to Wall Street analysts Eurobio-Scientific SA’s price is currently Overvalued.
Does Eurobio-Scientific SA pay dividends?
Eurobio-Scientific SA does not currently pay dividends.
What is Eurobio-Scientific SA’s EPS estimate?
Eurobio-Scientific SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eurobio-Scientific SA have?
Eurobio-Scientific SA has 10,248,871 shares outstanding.
What happened to Eurobio-Scientific SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Eurobio-Scientific SA?
Currently, no hedge funds are holding shares in FR:ALERS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eurobio-Scientific SA
Eurobio Scientific S.A. specializes in the conceptualization, development, and distribution of sophisticated diagnostic products. Its key therapeutic and research domains include transplantation, infectious illnesses, life sciences, and oncology. The company's portfolio features the Tetanus Quick Stick, an essential emergency diagnostic for rapidly determining a patient's tetanus vaccination status. It also distributes cell culture media, molecular biology reagents, and proprietary antibody solutions. Proprietary developments from Eurobio Scientific encompass the BJI InoPlex, a multiplex serological test for diagnosing prosthetic joint infections, and the EBX-044 PCR test, utilized for identifying SARS-CoV-2 variants. Its licensed offerings include AlloMap, a gene-expression profiling blood test designed for the ongoing surveillance of heart transplant recipients. The firm, initially named Diaxonhit, changed its corporate identity to Eurobio Scientific S.A. in June 2018. Founded in 1997, the company is headquartered in Les Ulis, France.
Technical Analysis
MAUNA KEA TECHNOLOGIES
―
Novacyt
―
Diagnostic Medical Systems
―
Ikonisys SA
―
Median Technologies
―